For men with the return of prostate cancer, a novel combined treatment can potentially give them an extended period before ...

Researchers report longer progression-free survival when Lutetium-177 was combined with standard radiotherapy for limited ...

Patients with recurring prostate cancer who were treated with a new PSMA-targeted radioligand therapy before stereotactic ...

Median progression-free survival (PFS) increased from 7.4 months with stereotactic body radiotherapy (SBRT) to 17.6 months with the addition of 177 lutetium (Lu) PNT2002 targeting prostate-specific ...

A bandage hiding a vicious scar from delicate cancer surgery provided a grim sign that feeble former President Joe Biden is ...

The median follow-up of 37 months showed that PSMAiSRT improved FFS and eugonadal FFS, with significant improvements in the ...

September is Prostate Cancer Awareness Month, and when many men choose to get check-ups.Though the month is nearly over, UAMS ...

A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly ...

Prostate cancer, a common malignancy in men, can rarely spread to the skin, a condition known as cutaneous metastasis. These skin lesions, often appea ...

Prostate involvement was first reported in IgG4-RD approximately 2 decades ago and comprises only 9.6% of cases.

Despite SBRT (radiation) to oligometastatic sites, prostate cancer progression still occurs in a majority of patients due to occult microscopic disease.